Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa dimethyl fumarate study in cutaneous T-cell lymphoma
2014-000924-11Phase 2Completed
- Sponsor
- Medical Faculty Mannheim of Heidelberg University
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fumaderm in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Medical Faculty Mannheim of Heidelberg University. Primary endpoint: Response rate after 24 weeks of DMF treatment. Started Mar 2015; status: completed.
02
Drugs
Fumaderm
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on 2014-000924-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000924-11.